San Antonio, TX – December 12, 2023 – A landmark study, poised to fundamentally redefine breast cancer screening guidelines, suggests that a personalized, risk-adapted approach is not only safer but also significantly more effective than the long-standing practice of routine annual mammograms for all women. The comprehensive research, unveiled today in JAMA and presented at the San Antonio Breast Cancer Symposium, indicates that by aligning screening frequency with an individual’s unique risk profile, it is possible to substantially lower the incidence of advanced cancer diagnoses while ensuring optimal care.
This groundbreaking revelation stems from the initial phase of the WISDOM study, which meticulously analyzed data from 46,000 women across the United States. Coordinated by the University of California, San Francisco (UCSF), the findings herald a pivotal shift in how breast cancer screening could be managed, moving decisively away from rigid, age-centric directives towards a dynamic system built upon thorough, individualized risk evaluation. The study challenges decades of conventional wisdom, proposing a more nuanced and patient-centric model that promises to revolutionize preventive oncology.
Main Facts: Redefining the Screening Paradigm
The core finding of the WISDOM study is unequivocal: tailoring breast cancer screening to a woman’s individual risk factors — including genetic predisposition, biological markers, lifestyle choices, health history, and breast density — offers superior outcomes compared to a blanket annual mammography recommendation. This personalized strategy demonstrated its ability to detect cancers at earlier, more treatable stages, particularly for high-risk individuals, without increasing the rate of advanced cancer diagnoses in the overall population.
Dr. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author, articulated the profound implications: "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice. The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Her statement underscores the urgent need for a paradigm shift, emphasizing that age alone is an insufficient determinant for screening frequency in the diverse landscape of breast cancer risk.
The study’s robust methodology, which compared traditional annual screening with a risk-stratified approach, involved grouping participants into four distinct risk categories. Each category received tailored recommendations ranging from delayed screening for the lowest-risk individuals to biannual screening with both mammography and MRI for the highest-risk cohort. Importantly, this adaptive model did not compromise diagnostic efficacy; rather, it optimized resource allocation and reduced potential harms associated with over-screening in low-risk populations.
Chronology: The Evolution of Screening and the Genesis of WISDOM
For much of the past half-century, breast cancer screening guidelines have largely been predicated on a one-size-fits-all model, primarily based on a woman’s age. The rationale was simple: as women age, their risk of developing breast cancer generally increases, thus justifying routine screening for broader age groups. This approach, while effective in reducing mortality rates to some extent, has faced increasing scrutiny from the medical community due to its inherent limitations and potential drawbacks.
The uniform screening schedule, often recommending annual mammograms starting at age 40 or 50, frequently led to both over-screening of women at low risk and under-screening of those at genuinely high risk. The former group might endure unnecessary anxiety, false positives, and the cumulative effects of radiation exposure, while the latter could miss crucial early detection opportunities. Research had long indicated that breast cancer risk is a complex interplay of genetic, environmental, and personal health factors, varying significantly from one individual to another, yet guidelines struggled to adapt to this nuanced understanding.
It was against this backdrop that the WISDOM study (Women Informed to Screen Depending On Measures of Risk) was conceived. Launched in 2016, the study was designed as a pragmatic, large-scale randomized trial to directly compare the efficacy and safety of traditional annual mammography against a personalized, risk-based screening strategy. UCSF served as the coordinating center, bringing together a consortium of institutions and experts dedicated to advancing breast health. The study’s ambitious goal was to gather irrefutable evidence that could pave the way for a more intelligent, individualized approach to breast cancer prevention and early detection.
Initially enrolling women typically targeted by screening guidelines, WISDOM later expanded its scope to include women as young as 30. This expansion was a strategic move aimed at identifying individuals who might face an elevated risk of aggressive early-onset cancers due to inherited genetic variants, a population often overlooked by traditional age-based screening protocols and genetic testing criteria. The phase one findings, drawing from the experiences of 46,000 participants, represent a significant milestone in this ongoing endeavor, offering a compelling evidence base for a transformative shift in clinical practice.
Supporting Data: Unpacking the WISDOM Methodology and Key Findings
The WISDOM study’s design was meticulously crafted to provide a robust comparison between the two screening strategies. Participants were randomized into two arms: one receiving conventional annual mammography, and the other following a personalized, risk-based screening regimen. To stratify risk, researchers employed well-validated risk models that integrated a comprehensive array of factors. These included:
- Age: While moving beyond age as the sole determinant, it remained a foundational component of risk assessment.
- Genetic Information: This involved testing for known pathogenic variants like BRCA1 and BRCA2, as well as evaluating polygenic risk scores (PRS), which combine the effects of numerous smaller DNA changes to provide a more refined risk estimate.
- Lifestyle Factors: Diet, physical activity, alcohol consumption, and other modifiable behaviors known to influence cancer risk were considered.
- Health History: Personal and family history of breast cancer, as well as other relevant medical conditions, contributed to the risk profile.
- Breast Density: Denser breast tissue can mask tumors on mammograms and is itself a risk factor for breast cancer.
Based on these comprehensive evaluations, participants were categorized into four distinct risk groups, each receiving tailored screening advice:
- Lowest Risk (26% of participants): Women in this category were advised to delay routine screening until age 50, or until an algorithmic assessment indicated their risk level had naturally risen to that of a typical 50-year-old woman. This approach aimed to prevent unnecessary screenings and associated anxieties in a population unlikely to benefit from early, frequent intervention.
- Average Risk (62% of participants): This largest group was recommended to undergo screening every two years, a frequency often advocated for women in the general population but now informed by a more precise understanding of their individual risk.
- Elevated Risk (8% of participants): For these women, annual mammograms were recommended, recognizing their heightened susceptibility and the need for more frequent surveillance.
- Highest Risk (2% of participants): This most vulnerable cohort received the most intensive screening protocol, advised to undergo screening twice a year, alternating between mammography and MRI, irrespective of their age. This aggressive strategy aimed to maximize early detection in individuals facing the greatest threat.
A crucial finding from the study was that the personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This outcome is paramount, as it validates the safety and effectiveness of a tailored strategy, demonstrating that reducing screening frequency for some does not equate to missed or delayed diagnoses for others. Moreover, the study observed significant patient acceptance of this novel approach: among participants who chose not to be randomized but joined an observational group, a remarkable 89% opted for risk-based screening, suggesting a strong preference for personalized care when given the choice.
Personalized Prevention for Higher-Risk Women: Beyond Screening
The WISDOM study extended its personalized approach beyond just screening frequency. Participants identified as having elevated or highest risk were also provided with customized guidance aimed at actively lowering their chances of developing breast cancer. This holistic support included:
- Access to an Online Decision-Making Tool: This interactive resource offered women detailed information about their specific risk factors and potential preventive strategies, empowering them to make informed choices about their breast health.
- Direct Contact with a Breast Health Specialist: This provided a crucial human element, offering personalized counseling, answering questions, and addressing individual concerns.
- Recommendations for Lifestyle Changes: Guidance covered actionable steps such as improving diet, increasing physical activity, and maintaining a healthy weight – all well-established factors in cancer prevention.
- Discussions about Preventive Medications: For eligible women, specialists initiated conversations about medications known to reduce breast cancer risk, such as selective estrogen receptor modulators (SERMs), allowing for shared decision-making.
This multi-faceted intervention for higher-risk individuals underscores the study’s commitment to comprehensive prevention, rather than solely focusing on early detection. As co-author Jeffrey A. Tice, MD, a UCSF professor of Medicine specializing in breast cancer risk assessment tools, aptly noted, "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer." This strategic allocation of resources not only benefits high-risk individuals but also optimizes the overall efficiency and cost-effectiveness of breast cancer care.
Expanding Genetic Testing Beyond Family History: A Game Changer
One of the most profound and potentially far-reaching contributions of the WISDOM study lies in its approach to genetic testing. Since its inception, the study has expanded its enrollment to over 80,000 women, including those as young as 30, with a specific focus on identifying individuals who may face an increased risk of aggressive early cancers due to inherited genetic variants.
The study’s most notable genetic finding challenges conventional clinical wisdom: a significant 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported absolutely no family history of the disease. Under current clinical guidelines, many of these women would typically not qualify for genetic testing, highlighting a critical gap in existing screening paradigms. This revelation suggests that universal or broader genetic screening could identify a substantial number of women who are currently unaware of their elevated risk, enabling earlier, life-saving interventions.
Beyond well-known pathogenic variants like BRCA1 and BRCA2, the WISDOM study also rigorously evaluated smaller DNA changes that can be combined into a polygenic risk score (PRS). This innovative approach, which aggregates the subtle effects of multiple common genetic variants, significantly improved the precision of risk predictions. The integration of PRS resulted in a notable 12% to 14% of participants being reassigned to a different risk category, demonstrating its power to refine individual risk profiles and ensure more accurate screening recommendations.
"This is one of the first studies to offer genetic testing to all women, regardless of family history," emphasized co-author Allison S. Fiscalini, MPH, of UCSF, who serves as director of the Athena Breast Health Network and the WISDOM study. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." This statement underscores the potential for genetic testing, when integrated into a holistic risk model, to unlock a new dimension of personalized preventive care.
Official Responses: Expert Voices on a Paradigm Shift
The release of the WISDOM study findings has generated considerable excitement and strong affirmations from the medical community, particularly from its lead investigators. Dr. Laura J. Esserman’s call for an immediate transformation of clinical guidelines resonates with a growing consensus that the current one-size-fits-all approach is outdated and inefficient. Her vision of a "personalized approach" that integrates "genetic, biological, and lifestyle factors" is seen as the logical next step in precision medicine for oncology.
Dr. Jeffrey A. Tice’s emphasis on the "efficient, effective approach" of reallocating resources from lower-risk to higher-risk women highlights the practical benefits for healthcare systems. In an era of increasing healthcare costs and resource constraints, optimizing screening strategies to target those most likely to benefit offers a compelling economic argument alongside the clinical advantages. This efficiency translates not only to better patient outcomes but also to a more sustainable model of preventive care.
Allison S. Fiscalini’s comments regarding the expanded role of genetic testing are particularly impactful. The revelation that many women with high-risk genetic variants lack a family history directly challenges current testing criteria, which often rely on a familial predisposition. This finding is a powerful argument for broadening access to genetic screening, potentially identifying thousands of women who could benefit from intensive surveillance or preventive measures before cancer develops. Her assertion that these results "could have a real impact on improving the safety and effectiveness of screening and prevention" reflects the study’s potential to save lives and reduce the burden of breast cancer.
Leading oncologists and public health experts, while cautious about immediate policy changes, have largely welcomed the WISDOM study’s findings as a significant advancement. Many believe this study provides robust evidence for what has been theoretically understood for years: that individual risk assessment is superior to broad population-based guidelines. The detailed methodology and the positive outcomes observed are expected to fuel discussions among national guideline-setting bodies, such as the American Cancer Society and the U.S. Preventive Services Task Force, potentially ushering in a new era of risk-stratified recommendations.
Implications: Reshaping the Future of Breast Cancer Care
The implications of the WISDOM study are far-reaching, promising to reshape not only breast cancer screening guidelines but also the broader landscape of preventive healthcare.
For Patients:
The most significant benefit for patients will be a move towards more tailored and less anxiety-inducing screening experiences. Women at lower risk could avoid unnecessary biopsies, false positives, and the psychological burden associated with over-screening. Conversely, those at higher risk would receive more frequent and intensive surveillance, increasing the likelihood of detecting cancer at its earliest, most curable stages. The personalized prevention strategies, including lifestyle guidance and discussions about medications, empower women to take a more active role in managing their breast health.
For Healthcare Systems:
Implementing a risk-based screening strategy could lead to a more efficient allocation of healthcare resources. By concentrating intensive screening methods like MRI on high-risk populations, healthcare systems could potentially reduce costs associated with unnecessary mammograms and follow-up procedures for low-risk individuals. This "smart screening" approach maximizes the impact of preventive efforts while optimizing the use of expensive diagnostic technologies.
For Clinical Guidelines and Policy:
The findings from WISDOM are expected to exert considerable pressure on national and international bodies responsible for establishing cancer screening guidelines. The robust data supporting risk-based screening, particularly the insights into genetic testing, will likely prompt a re-evaluation of existing recommendations. This could lead to the adoption of multi-factorial risk assessment tools as standard practice, fundamentally altering how primary care providers and gynecologists counsel their patients on breast cancer screening. The study also opens the door for a wider discussion on universal genetic testing, or at least expanding access far beyond current family history-based criteria.
Future Research: WISDOM 2.0 and Beyond:
The work is far from over. Researchers are actively refining risk assessment through the ongoing WISDOM 2.0 study, which is currently enrolling participants. The primary goal of this next phase is to further enhance the identification of women who face a higher likelihood of developing aggressive breast cancers and to develop even more sophisticated screening and prevention strategies tailored to their long-term health needs. This iterative process of research and refinement promises to continually improve the precision and effectiveness of breast cancer care.
The WISDOM study represents a monumental leap forward in the quest for precision medicine in oncology. By demonstrating the superior efficacy and safety of personalized, risk-based screening, it lays the groundwork for a future where every woman receives the exact level of care she needs, when she needs it, ultimately saving lives and transforming the battle against breast cancer.
Co-Authors and Institutions:
The collaborative effort involved numerous researchers from UCSF, including Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Additional investigators contributed from UC Los Angeles, UC Irvine, UC San Diego, San Francisco VA Health Care System, Sanford Health in North Dakota, University of Chicago, Diagnostic Center of Miami, University of Alabama, Virginia Commonwealth University, Weill Cornell Medicine in New York, and the Karolinska Institutet in Stockholm.
Funding and Conflicts of Interest:
Study support was provided by the Patient Center Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation, among other sources detailed in the published paper. Dr. Esserman reported serving as a medical advisory panel member for Blue Cross Blue Shield and receiving author fees from the UpToDate electronic medical information resource. Disclosures for other investigators are available in the JAMA publication.
About the Author
